Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUQ1DO)

• Drug Name: ITI-007 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Phase 3	[1]
Insomnia	7A00-7A0Z	Phase 3	[2]
Schizophrenia	6A20	Phase 3	[2]
Major depressive disorder	6A70.3	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 21302490
  CAS Number: CAS 313369-37-8
  TTD Drug ID: DMUQ1DO
  ACDINA Drug ID: D01228

Molecule-Related Drug Atlas

Drug(s) Targeting Serotonin transporter (SERT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[4]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[5]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Vortioxetine	DM6F1PU	Major depressive disorder	6A70.3	Approved	[7]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[8]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[9]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[10]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[6]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[6]
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[6]

Drug(s) Targeting 5-HT 2A receptor (HTR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[11]
ZOTEPINE	DMF3VXA	Anxiety disorder	6B00-6B0Z	Approved	[12]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[13]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[7]
Lurasidone hydrochloride	DMCVPXO	Schizophrenia	6A20	Approved	[14]
Aniracetam	DMOIFW0	Cerebrovascular ischaemia	8B1Z	Approved	[15]
lumateperone tosylate	DMQ8HOJ	Schizophrenia	6A20	Approved	[16]
Sarpogrelate	DMGLP6S	Diabetic complication	5A2Y	Approved	[17]
Pimavanserin	DMR7IVC	Parkinson disease	8A00.0	Approved	[18]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[19]

Drug(s) Targeting 5-HT receptor (5HTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[20]
Paliperidone	DM7NPJS	Psychotic disorder	6A20-6A25	Approved	[21]
Ramosetron	DMH7GN8	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[20]
Pizotyline	DMV74ZH	Headache	8A80-8A84	Approved	[21]
Tandospirone	DMPHWU6	Anxiety disorder	6B00-6B0Z	Approved	[20]
Nafronyl	DMVMQ1L	Cerebrovascular ischaemia	8B1Z	Approved	[21]
Fenfluramine	DM0762O	Dravet syndrome	8A61.11	Phase 3	[22]
MIN-117	DMSLIW6	Major depressive disorder	6A70.3	Phase 2	[1]
Lu-AA34893	DM2ZUXK	Anxiety disorder	6B00-6B0Z	Phase 2	[23]
SEP--4199	DMA12HB	Bipolar disorder	6A60	Phase 2	[24]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2A receptor (HTR2A)	TTJQOD7	5HT2A_HUMAN	Antagonist	[3]
5-HT receptor (5HTR)	TT85JO3	NOUNIPROTAC	Antagonist	[1]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Antagonist	[3]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT02469155) A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment.
• [3] Clinical pipeline report, company report or official report of Intra-Cellular Therapies, Inc.
• [4] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
• [5] Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [7] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [8] Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
• [9] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [10] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
• [11] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [12] Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
• [13] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [14] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [15] Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [17] Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
• [18] Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
• [19] Clinical pipeline report, company report or official report of Lundbeck.
• [20] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [21] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [22] Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
• [23] Encyclopedia of Psychopharmacology. Ian Stolerman. 2010. Page(105).
• [24] ClinicalTrials.gov (NCT03543410) A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression. U.S. National Institutes of Health.